Pharmaceutical

EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity

The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.

Sep 14, 2024 - 04:00
EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity
The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.
Read the original article

Tags:

Previous Article

Moderna cuts five programmes to save $1.1bn in R&D costs

Next Article

Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Sanders takes aim at US drug prices of Novo’s Ozempic a...

Apr 27, 2024

STAT+: Johnson & Johnson sues to stop Medicare negotiation

STAT+: Johnson & Johnson sues to stop Medicare negotiation

Jul 18, 2023

STAT’s Inaugural Diversity Report and Commitment to a Workplace of Diversity and Inclusion

STAT’s Inaugural Diversity Report and Commitment to a W...

Jul 6, 2023